Story

Evotec Shares Fall as H1 Results Confirm Steep Guidance Cut

ENTHMSVIIDZHZH-TWJAKOHI
Aug 13, 20262 min read
Evotec Shares Fall as H1 Results Confirm Steep Guidance Cut
Text size
Background

Shares in German biotech firm Evotec AG (EVTG) fell on Tuesday after the company's full first-half financial report solidified the stark profit warning it issued in July. The stock traded down 2.2% to €3.765, nearing its 52-week low as investors digested the extent of the firm's operational and financial challenges.

H1 Results Detail Downturn

The company's H1 2026 report provided a detailed view of the difficulties flagged last month. According to the release, key second-quarter figures included:

  • Group Revenue: Dropped 16.2% year-over-year to €143.5 million.
  • Adjusted Group EBITDA: Deteriorated significantly to a loss of €20.8 million, a 320.3% decline from the prior-year period.

Evotec attributed the poor performance to delayed milestone payments from partnerships and a slower-than-anticipated conversion of commercial activities into recognized revenue. Compounding the issue, the company's Just-Evotec Biologics segment, previously seen as a key growth driver, also reported a steep revenue decline in the first half.

Bleak Outlook and Investor Concerns

Sample IUX Markets – In-articleAd

The results confirmed a sharply reduced full-year 2026 forecast. Evotec now expects revenue between €570–€610 million, a substantial reduction from its original target of €700–€780 million. More critically, the company anticipates an adjusted EBITDA loss of €70–€105 million, a stark reversal from its previous guidance for a profit of up to €40 million.

The key question for investors is whether the revenue shortfall is a temporary timing issue, with payments potentially pushed into 2027, or a more structural problem with the business model. Confidence is further dampened by the company's "Horizon" cost-saving program, which is expected to deliver only 20–30% of its targeted €75 million in annual savings this year.

Analyst Sentiment Remains Negative

The confirmed results have done little to reverse the negative sentiment that has built since July's pre-announcement. Following that warning, Berenberg downgraded Evotec to 'Hold' from 'Buy' and slashed its price target to €3.60 from €9.40, citing a "near-total loss of near-term visibility." Deutsche Bank also trimmed its price target to €3.50, maintaining a 'Hold' rating.

Read next

More on Stocks
Back to latest news

LATEST